News
Navin Molecular is pleased to announce, as part of its ongoing commitment to sustainability, its collaboration with Evertreen.com, a company at the leading edge of efforts aimed at reducing (and reversing) deforestation worldwide.
Through our collaboration we aim to both support reforestation efforts in India and reduce our environmental footprint as a result, reinforcing our owner Vishad Mafatlal’s dedication to making a positive difference by our actions.
We believe that partnering with Evertreen in this way is one of the most effective ways to both lower our carbon footprint whilst also providing a healthier planet for the generations to come. With Evertreen’s cutting edge technology we are able to monitor our progress in real time, with the GPS coordinates of our plantation available publicly, making it easy for customers to see the impact of contributions we have made on their behalf.

Our CCO recently took part in a wide-ranging discussion on current trends in raw material and API intermediate sourcing. The link to the full article is below:
https://www.pharmtech.com/view/diversifying-the-supply-of-raw-materials
12 July 2024

Following the announcement of the construction of our new “GMP-4” manufacturing facility, the story was featured in a number of industry publications. The below links have more details.
As you know, Google ranks websites partly based on the number of links to that site, so I think adding all of the below will help our search engine ranking.
https://www.pharmoutsourcing.com/1315-News/613867-Navin-Molecular-to-Invest-up-to-35M-to-Expand-GMP-Manufacturing-Capabilities/?catid=6263
https://manufacturingchemist.com/navin-molecular-to-invest-up-to-35-million
https://www.biospectrumindia.com/news/97/24863/navin-molecular-to-invest-35-m-for-expanding-manufacturing-capabilities.html
https://biovoicenews.com/navin-molecular-invests-35-million-to-expand-gmp-manufacturing-capabilities/
https://www.chemanager-online.com/en/news/navin-molecular-plans-eu326-million-expansion-gmp-manufacturing
https://www.echemi.com/cms/1958679.html
https://www.lskh.digital/news/navin-molecular-to-invest-up-to-35-million-to-expand-gmp-manufacturing-capabilities/
https://drug-dev.com/navin-molecular-to-invest-up-to-35-million-to-expand-gmp-manufacturing-capabilities/
https://chemicalweekly.com/news/latestnews/article/632
12 July 2024

Our CCO Jordi Robinson was recently interviewed by Contract Pharma and asked “What are “3 Key Trends” shaping the CDMO industry in 2024 and beyond?”
You can read his thoughts by following the below link. Let us know on our LinkedIn page (https://www.linkedin.com/company/navin-molecular-cdmo) if you agree with Jordi’s thoughts on the future of the CDMO industry.
27 June 2024

Our CCO Jordi Robinson recently sat down with Pharmtech.com as part of their regular “Drug Digest” video series. In a wide-ranging interview, which starts around 27.50, Jordi was asked his opinions on the major changes in the outsourcing landscape in the last few years, including – but not limited – to the current impact the Biosecure act is having on the industry’s attitude to outsourcing.
Access the video here
19 June 2024

Navin Fluorine Board approves Rs 288 Cr (approx. USD 35M) capital investment for the construction of cGMP-4 at our Dewas facility to add additional 200kL multi-purpose capacity.
6 February 2024